ClinicalTrials.gov Search Results 09/18/2017

	NCT Number	Title	Other Names	Recruitment	Conditions	Interventions	Characteristics	Population	Sponsor/ Collaborators	Funded Bys	Dates
1	NCT02617056	Objective Assessment of Behavioral Associations of Patients With Dementia	Title Acronym Other Ids •N1932-P •RX001932-01	Recruiting	•Dementia •Psychomotor Agitation		Study Types: Observational Phase: Study Designs: •Observational Model: Ecologic or Community •Time Perspective: Prospective Outcome Measures: •Electrodermal activity •Association of behaviors with electrodermal activity	Enrollment: 60 Age: Child, Adult, Senior Sex: All	•VA Office of Research and Development •University of Massachusetts Worcester	•U.S. Fed •Other	Study Start: January 1, 2016 Primary Completion: December 29, 2017 Study Completion: December 29, 2017 First Received: November 25, 2015 Last Updated: September 6, 2017 Last Verified: September 2017 Results First Received: No Study Results Posted
2	NCT03033875	Testing Tele-Savvy, an On-line Psychoeducation Program for Dementia Family Caregivers	Title Acronym Other Ids •IRB00092812 •1R01AG054079-01	Recruiting	•Alzheimer Disease •Dementia	•Behavioral: Tele-Savvy •Behavioral: Healthy Living Education Program	Study Types: Interventional Phase: Study Designs: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Other Outcome Measures: •Change in Cornell Scale for Depression in Dementia (CSDD) Score •Change in Alzheimer's Disease Related Quality of Life (ADRQL) Score •Change in Perceived Stress Scale (PSS) Score •Change in Center for Epidemiological Studies Depression Scale - Revised (CESD-R) Score •Change in State-Trait Anxiety Inventory (STAI) Score •Change in Patient-Reported Outcomes Measurement Information System (PROMIS) Anxiety - short form Score •Change in Zarit Burden Inventory (ZBI) Score •Change in Dyadic Relationship Scale Score •Change in Ways of Coping Scale Score •Change in Revised Memory and Behavior Problem Checklist (RMBPC) Score •Change in Self-Rated Health Score •Change in the Caregiver Assessment of Behavioral Skill - Self Report (CAB-SR) Measure Score •Change in the Pearlin Measure Score	Enrollment: 75 Age: 18 Years and older (Adult, Senior) Sex: All	•Emory University •National Institute on Aging (NIA)	•Other •NIH	Study Start: May 18, 2017 Primary Completion: November 30, 2020 Study Completion: November 30, 2020 First Received: January 25, 2017 Last Updated: June 15, 2017 Last Verified: June 2017 Results First Received: No Study Results Posted

3	NCT02697721	Powerful Tools for Caregivers of Dementia Patients	Title Acronym: PTC-dementia Other Ids: 6AZ09	Recruiting	•Caregivers •Dementia •Alzheimer Disease	•Behavioral: Powerful Tools for Caregivers •Other: Control with delayed intervention	Study Types: Interventional Phase: Study Designs: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Caregiver Burden •Frequency and reaction to care recipient behavioral and psychological symptoms of dementia •Frequency of care recipient agitated behaviors •Activity parameters as assessed by FitBit •Depressive symptoms •Caregiving Self-Efficacy •Self-rated health •Life satisfaction •Perceived change •Neuropsychiatric symptoms in care recipients	Enrollment: 60 Age: 18 Years and older (Adult, Senior) Sex: All	•Florida State University •Florida Department of Health, Ed and Ethel Moore Alzheimer's Disease Research Program	•Other	Study Start: February 2016 Primary Completion: January 2018 Study Completion: First Received: February 17, 2016 Last Updated: August 24, 2016 Last Verified: August 2016 Results First Received: No Study Results Posted
4	NCT03075007	Brain Vascular Disease in Aging and Dementia	Title Acronym: Other Ids: •AAAR1423 •2R56AG034189-06A1	Recruiting	•Alzheimer Disease •White Matter Hyperintensities •Dementia •Aging	•Radiation: Florbetaben F18 •Procedure: Transcranial Doppler	Study Types: Observational Phase: Study Designs: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: •PET amyloid Standard Uptake Value ratio (SUVr) values •Transcranial Doppler (TCD) dynamic autoregulatory dysfunction	Enrollment: 20 Age: 60 Years and older (Adult, Senior) Sex: All	•Columbia University •National Institute on Aging (NIA)	•Other •NIH	Study Start: May 23, 2017 Primary Completion: November 2019 Study Completion: November 2019 First Received: March 6, 2017 Last Updated: June 5, 2017 Last Verified: June 2017 Results First Received: No Study Results Posted
5	NCT02106065	VA Cultivating Access to Resources, Education, and Skills for Dementia Caregivers	Title Acronym: VA CARES Other Ids: •E1240-W •5IK2RX001240-02	Recruiting	•Dementia •Caregivers •Neurodegenerative Diseases •Brain Diseases	•Behavioral: Education and Skill-Building Rehabilitation (ESBR) •Other: Supplemental Education Materials	Study Types: Interventional Phase: Phase 1 Study Designs: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Single (Outcomes Assessor) •Primary Purpose: Supportive Care Outcome Measures: •change in caregiver quality of life •change in caregiver depressive symptoms •change in community tenure (care recipient) •change in long-term care placement status (care recipient) •change in all-cause mortality status (care recipient)	Enrollment: 150 Age: 18 Years and older (Adult, Senior) Sex: All	•VA Office of Research and Development	•U.S. Fed	Study Start: February 21, 2014 Primary Completion: December 31, 2019 Study Completion: December 31, 2019 First Received: March 27, 2014 Last Updated: June 8, 2017 Last Verified: June 2017 Results First Received: No Study Results Posted

6	NCT02678767	Ferumoxytol-enhanced Imaging and Mapping in neuroAIDS	Title Acronym Other Ids •2013-077 •H032 •1R21NS087951-01A1	Recruiting	•AIDS Dementia Complex	•Drug: Ferumoxytol	Study Types Interventional Phase Phase 2 Study Designs •Allocation: Non-Randomized •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Screening Outcome Measures •Change in the proportion of abnormal MRIs •Change in quantitative susceptibility mapping (QSM)	Enrollment 30 Age 40 Years to 65 Years (Adult) Sex All	•Beau Nakamoto •Hawaii Pacific Health •University of Hawaii •National Institute of Neurological Disorders and Stroke (NINDS)	•Other •NIH	Study Start February 2015 Primary Completion April 2017 Study Completion April 2017 First Received February 2, 2016 Last Updated October 25, 2016 Last Verified October 2016 Results First Received No Study Results Posted
7	NCT02368132	Delivery Models of Caregiver Support and Education	Title Acronym Other Ids •IIR 14-080 •01548	Recruiting	•Dementia	•Behavioral: Group Delivered TEP •Behavioral: Individual Delivered TEP	Study Types Interventional Phase Study Designs •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Single (Outcomes Assessor) •Primary Purpose: Supportive Care Outcome Measures •Caregiver Perceived Burden with Zarit Burden Interview •Caregiver Distress in Response to Dementia-Related Symptoms with Revised Memory and Behavior Problems Checklist •Caregiver Overall Mental Functioning with the 12 Item Short Form Health Survey (SF12)	Enrollment 405 Age 18 Years and older (Adult, Senior) Sex All	•VA Office of Research and Development	•U.S. Fed	Study Start May 13, 2016 Primary Completion June 1, 2019 Study Completion June 1, 2019 First Received February 9, 2015 Last Updated June 7, 2017 Last Verified June 2017 Results First Received No Study Results Posted
8	NCT01052350	PET Imaging in Parkinson Disease Dementia	Title Acronym Other Ids 06-0706	Recruiting	•Parkinson's Disease		Study Types Observational Phase Study Designs •Observational Model: Case Control •Time Perspective: Prospective Outcome Measures	Enrollment 320 Age 50 Years and older (Adult, Senior) Sex All	•Washington University School of Medicine	•Other	Study Start August 2006 Primary Completion July 2030 Study Completion July 2030 First Received January 15, 2010 Last Updated January 12, 2016 Last Verified January 2016 Results First Received No Study Results Posted
9	NCT02759887	Relationship Between Down Syndrome (DS) and Alzheimer's Disease (AD)	Title Acronym Other Ids PHX-16-0028-70-03	Recruiting	•Down Syndrome •Alzheimer's Dementia	•Procedure: biospecimen collection •Other: cognitive assessments •Other: caregiver questionnaire •Procedure: Florbetapir F18 imaging •Procedure: MRI •Procedure: Fludeoxyglucose F18 (FDG) •Procedure: Tau Pet •Procedure: Actigraphy	Study Types Interventional Phase Study Designs •Allocation: Non-Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Diagnostic Outcome Measures •Florbetapir PET - change between timeframes •tau PET - change between timeframes •FDG PET - change between timeframes •MRI - change between timeframes •dried blood spot collection (DBSC) analysis - change between timeframes	Enrollment 40 Age 21 Years and older (Adult, Senior) Sex All	•St. Joseph's Hospital and Medical Center, Phoenix •Banner Alzheimer's Institute, Phoenix •Translational Genomics Research Institute (TGEN), Phoenix	•Other	Study Start November 2016 Primary Completion March 2019 Study Completion June 2019 First Received April 15, 2016 Last Updated November 1, 2016 Last Verified November 2016 Results First Received No Study Results Posted

10	NCT03070535	APOE Genotype and Diet Influences on Alzheimer's Biomarkers	Title Acronym Other Ids 50573-D	Recruiting	•Alzheimer's Disease; Dementia	•Other: HIGH and LOW meal ingestion	Study Types Interventional Phase Study Designs •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: Single (Participant) •Primary Purpose: Basic Science Outcome Measures •Lipid biomarkers •APOE lipidation •Insulin	Enrollment 80 Age 55 Years and older (Adult, Senior) Sex All	•University of Washington	•Other	Study Start September 2016 Primary Completion May 31, 2020 Study Completion May 31, 2020 First Received February 27, 2017 Last Updated February 27, 2017 Last Verified February 2017 Results First Received No Study Results Posted
11	NCT02702102	Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies	Title Acronym Other Ids •AAAQ0756 •2P50AG008702-26	Recruiting	•Diffuse Lewy Body Disease •Dementia With Lewy Bodies •Parkinson's Disease Dementia	•Drug: 11C-PBR28	Study Types Interventional Phase Phase 2 Study Designs •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Diagnostic Outcome Measures •Absolute 11C-PBR28 binding (total distribution volume corrected for free fraction in plasma) •Relative 11C-PBR28 binding	Enrollment 16 Age 60 Years and older (Adult, Senior) Sex All	•William Charles Kreisl •National Institute on Aging (NIA) •Columbia University	•Other •NIH	Study Start December 2015 Primary Completion August 2017 Study Completion August 2017 First Received March 3, 2016 Last Updated December 7, 2016 Last Verified December 2016 Results First Received No Study Results Posted
12	NCT02490137	Brain Changes With Game Training in Aging	Title Acronym BrainGame Other Ids UWisconsin	Recruiting	•Aging •Dementia	•Behavioral: Race Car Video Game	Study Types Interventional Phase Study Designs •Allocation: Non-Randomized •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Basic Science Outcome Measures •MRI: Mean Diffusivity •MRI: Structural Morphometry	Enrollment 40 Age 50 Years to 80 Years (Adult, Senior) Sex All	•University of Wisconsin, Madison	•Other	Study Start June 2015 Primary Completion August 2017 Study Completion August 2017 First Received July 1, 2015 Last Updated October 25, 2016 Last Verified October 2016 Results First Received No Study Results Posted

13	NCT02014246	Genetic Characterization of Movement Disorders and Dementias	Title Acronym Other Ids •999903329 •03-AG-N329	Recruiting	•Ataxia •Dystonia •Parkinson's Disease •Amyotrophic Lateral Sclerosis •Corticobasal Degeneration •Multiple System Atrophy •Alzheimer's Disease •Lewy Body Dementia •Parkinson Disease-Dementia •Dentatorubral-pallidoluysian Atrophy •Creutzfeldt-Jakob Disease and Fatal Familial Insomnia •Fragile X-associated Tremor/Ataxia Syndrome •Krabbe's Disease •Niemann-Pick Disease, Type C •Neuronal Ceroid Lipofuscinosis		Study Types Observational Phase Study Designs •Observational Model: Case-Control •Time Perspective: Other Outcome Measures Identify and characterize genetic contributions to etiology for movement disorders, such as dystonia, Parkinson's disease, and dementias, such as Alzheimer's disease, Lewy Body Dementia, frontotemporal dementia.	Enrollment 12000 Age 2 Years and older (Child, Adult, Senior) Sex All	•National Institute on Aging (NIA) •National Institutes of Health Clinical Center (CC)	•NIH	Study Start February 12, 2003 Primary Completion December 31, 2017 Study Completion December 31, 2017 First Received December 12, 2013 Last Updated June 30, 2017 Last Verified April 11, 2017 Results First Received No Study Results Posted
14	NCT02915939	The Residential Care Transition Module	Title RCTM Acronym Other Ids R01AG048931	Recruiting	•Alzheimer Disease •Dementia	•Behavioral: The Residential Care Transition Module	Study Types Interventional Phase Study Designs •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Single (Outcomes Assessor) •Primary Purpose: Supportive Care Outcome Measures •Change in care-related strain •Change in burden: Zarit Burden Interview •Change in stress: Perceived Stress Scale	Enrollment 240 Age 21 Years and older (Adult, Senior) Sex All	•University of Minnesota - Clinical and Translational Science Institute •Johns Hopkins University •New York University School of Medicine •Benjamin Rose Institute •Emory University	•Other	Study Start December 2016 Primary Completion May 2021 Study Completion May 2021 First Received September 19, 2016 Last Updated March 13, 2017 Last Verified September 2016 Results First Received No Study Results Posted
15	NCT01353430	Characterization of Inclusion Body Myopathy Associated With Paget's Disease of Bone and Frontotemporal Dementia (IBMPFD)	Title Acronym Other Ids VK2007-5832	Recruiting	•Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia •Paget Disease of Bone •Frontotemporal Dementia •Myopathy		Study Types Observational Phase Study Designs •Observational Model: Case Control •Time Perspective: Cross-Sectional Outcome Measures	Enrollment 50 Age 18 Years and older (Adult, Senior) Sex All	•University of California, Irvine	•Other	Study Start January 2000 Primary Completion December 2025 Study Completion First Received January 26, 2011 Last Updated May 12, 2011 Last Verified May 2011 Results First Received No Study Results Posted

16	NCT02347202	Tools for Distance Delivery of an Evidence-based AD Family Caregiver Intervention	Title Acronym Other Ids 14-01185	Recruiting	•Alzheimer's Disease •Dementia	•Other: Online counseling via Zoom teleconferencing •Other: Telephone support as needed	Study Types Interventional Phase Study Designs •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Supportive Care Outcome Measures •Differences in depressive symptoms between groups (One-way analysis of variance, questionnaire) •Differences in reactions to problem behaviors between groups (questionnaire) •Differences in satisfaction with social support between groups (questionnaire)	Enrollment 240 Age 21 Years to 125 Years (Adult, Senior) Sex All	•New York University School of Medicine	•Other	Study Start October 2015 Primary Completion December 31, 2017 Study Completion December 31, 2017 First Received January 9, 2015 Last Updated April 19, 2017 Last Verified April 2017 Results First Received No Study Results Posted
17	NCT02022943	Alzheimer's Prevention Registry: A Program to Accelerate Enrollment Into Studies	Title Acronym APR Other Ids APR	Recruiting	•Alzheimer's Disease •Dementia		Study Types Observational Phase Study Designs Outcome Measures •Number of individuals enrolled into Alzheimer's prevention studies •Number of individuals referred to Alzheimer's prevention research studies / sites	Enrollment 500000 Age 18 Years to 110 Years (Adult, Senior) Sex All	•Banner Health	•Other	Study Start May 2012 Primary Completion January 2030 Study Completion January 2030 First Received December 23, 2013 Last Updated November 18, 2016 Last Verified November 2016 Results First Received No Study Results Posted
18	NCT01782157	Smart Environment Technology for Longitudinal Behavior Analysis and Intervention	Title Acronym CASAS/HH Other Ids R01EB015853-01A1	Recruiting	•Dementia		Study Types Observational Phase Study Designs •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures •Change from Baseline in Clinical Dementia Rating •Change from Baseline in Amount of Caregiver Assistance	Enrollment 42 Age 75 Years and older (Senior) Sex All	•Washington State University •National Institute for Biomedical Imaging and Bioengineering (NIBIB)	•Other •NIH	Study Start January 2013 Primary Completion December 2017 Study Completion December 2017 First Received December 18, 2012 Last Updated December 9, 2015 Last Verified December 2015 Results First Received No Study Results Posted
19	NCT01891383	Clinical Characteristics of Dementias That Occur Remotely After Traumatic Brain Injury in Retired Military Personnel	Title Acronym Other Ids •ERMS# 12lO9006 •NEU-92-1855	Recruiting	•Dementia •Traumatic Brain Injury (TBI) •Mild Cognitive Impairment (MCI) •Chronic Traumatic Encephalopathy (CTE) •Post-traumatic Stress Disorder (PTSD)		Study Types Observational Phase Study Designs •Observational Model: Case Control •Time Perspective: Cross-Sectional Outcome Measures •Prevalence of dementia or MCI in the two groups (TBI versus no TBI) •Characterization of the types of dementia or MCI that occur in the two groups (TBI or no TBI)	Enrollment 150 Age 50 Years to 95 Years (Adult, Senior) Sex All	•Uniformed Services University of the Health Sciences •University of California, San Francisco	•U.S. Fed •Other	Study Start July 2013 Primary Completion June 2016 Study Completion August 2016 First Received June 25, 2013 Last Updated December 30, 2015 Last Verified December 2015 Results First Received No Study Results Posted

20	NCT02140983	Effects of Liraglutide on Hippocampal Structure and Function in Aging Adults With Prediabetes	Title Acronym: LGT Other Ids: 25076	Recruiting	•Insulin Resistance •Dementia	•Drug: Liraglutide •Drug: Placebo	Study Types: Interventional Phase: Study Designs: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Triple (Participant, Care Provider, Outcomes Assessor) Outcome Measures: •Cognitive Outcomes •OGTT	Enrollment: 80 Age: 50 Years to 70 Years (Adult, Senior) Sex: All	•Stanford University •American Diabetes Association	•Other	Study Start: August 2013 Primary Completion: February 2017 Study Completion: February 2017 First Received: January 27, 2014 Last Updated: April 19, 2016 Last Verified: April 2016 Results First Received: No Study Results Posted
21	NCT02690896	Caregiver Burden and Depression: Caring for Those Who Care for Others	Title Acronym: Other Ids: SBE-15-11548	Recruiting	•Dementia •Alzheimer's Disease	•Behavioral: UCF Caregiver Support Group •Behavioral: Community Support Groups	Study Types: Interventional Phase: Study Designs: •Allocation: Non-Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: •Change in Long-Term Care Utilization based on Caregiver Report •Neuropsychiatric symptoms •Caregiver strain •Caregiver depression •Caregiver preparedness •Satisfaction Survey •Stress hormone level •Daily stress inventory •Subjective stress •Emotional affective state	Enrollment: 100 Age: 18 Years and older (Adult, Senior) Sex: All	•University of Central Florida •Alzheimer's and Dementia Resource Center	•Other	Study Start: January 2016 Primary Completion: August 2017 Study Completion: August 2020 First Received: January 11, 2016 Last Updated: May 3, 2016 Last Verified: May 2016 Results First Received: No Study Results Posted
22	NCT00064870	Alzheimer's Disease Genetics Study	Title Acronym: NCRAD Other Ids: •IA0042 •U24AG021886 •NIH grant U24 AG21886	Recruiting	•Alzheimer Disease •Late Onset Alzheimer Disease •Dementia		Study Types: Observational Phase: Study Designs: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: Distribute biological specimens to qualified investigators for use in their research studies.	Enrollment: 3000 Age: Child, Adult, Senior Sex: All	•Indiana University •National Institute on Aging (NIA)	•Other •NIH	Study Start: June 2002 Primary Completion: July 2021 Study Completion: July 2021 First Received: July 14, 2003 Last Updated: November 4, 2016 Last Verified: November 2016 Results First Received: No Study Results Posted

23	NCT02778971	Implications for Management of PET Amyloid Classification Technology	Title Acronym Other Ids IMPACT IMPACT-1	Recruiting	•Mild Cognitive Impairment •Dementia •Alzheimer's Disease	•Drug: [18F]Flutemetam	Study Types Phase Study Designs Outcome Measures Observational •Observational Model: Case-Only •Time Perspective: Prospective •Proportion of care practices changed after amyloid PET scan •Proportion of drug management options changed after amyloid PET •Change in % likelihood of Alzheimer's disease (AD) diagnosis after amyloid PET scan •Proportion of change in leading diagnosis after amyloid PET •Change in physician confidence in leading diagnosis •Change in care partner's confidence in diagnosis after amyloid PET •Change in care partner satisfaction with evaluation after amyloid PET •Change in care partner assessment of the quality of evaluation after amyloid PET •Proportion of care partners finding amyloid PET scan worthwhile •Proportion exhibiting increased behavior disturbance during amyloid scan visit •Proportion exhibiting increased behavior disturbance when the diagnosis is given •Percentage of recommended care practices adhered to after amyloid PET scan •Percentage of recommended drug management adhered to after amyloid PET scan	Enrollment Age Sex 50 45 Years to 90 Years (Adult, Senior) All	•University of Utah	•Other	Study Start Primary Completion Study Completion First Received Last Updated Last Verified Results First Received June 2016 June 2018 June 2019 May 6, 2016 July 5, 2017 July 2017 No Study Results Posted
24	NCT01816152	Methodology Issues in a Tailored Light Treatment for Persons With Dementia	Title Acronym Other Ids R01AG034157	Recruiting	•Sleep Disturbances •Depression	•Other: Tailored Active intervention •Other: Inactive intervention	Study Types Phase Study Designs Outcome Measures Interventional •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: Triple (Participant, Care Provider, Outcomes Assessor) •Primary Purpose: Treatment •Actigraphy •Light/dark patterns •Subjective Sleepiness •Depression •Activity of Daily Living •Agitation	Enrollment Age Sex 60 65 Years and older (Adult, Senior) All	•Rensselaer Polytechnic Institute	•Other	Study Start Primary Completion Study Completion First Received Last Updated Last Verified Results First Received December 2010 December 2018 April 2019 March 15, 2013 October 5, 2016 October 2016 No Study Results Posted

25	NCT00821132	Genetics of Familial and Sporadic ALS	Title Acronym: ALS Other Ids: •Lab01 •RO1N505641-04	Recruiting	•Amyotrophic Lateral Sclerosis (ALS) •Familial Amyotrophic Lateral Sclerosis •Amyotrophic Lateral Sclerosis With Frontotemporal Dementia •Lou Gehrig's Disease •Motor Neuron Disease •Primary Lateral Sclerosis	•Other: Genetic study of ALS families	Study Types: Observational Phase: Study Designs: Observational Model: Family-Based Outcome Measures: Identification of genes that increase risk for sporadic ALS or cause inherited ALS.	Enrollment: 15000 Age: 18 Years and older (Adult, Senior) Sex: All	•Northwestern University	•Other	Study Start: January 1991 Primary Completion: December 2019 Study Completion: December 2022 First Received: January 9, 2009 Last Updated: January 4, 2017 Last Verified: January 2017 Results First Received: No Study Results Posted
26	NCT02817074	MIND Diet Intervention and Cognitive Decline	Title Acronym: MIND Other Ids: •R01 AG051641 •1R01AG052583-01	Recruiting	•Cognitive Decline •Dementia •Alzheimer Disease •Vascular Dementia	•Behavioral: MIND Diet •Behavioral: Mild Weight Loss	Study Types: Interventional Phase: Phase 3 Study Designs: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Single (Outcomes Assessor) •Primary Purpose: Prevention Outcome Measures: •Change in global cognitive score •Change in brain MRI total brain /intracranial volume (cubic centimeters) and hippocampal/intracranial volume (cubic centimeters)	Enrollment: 600 Age: 65 Years to 84 Years (Adult, Senior) Sex: All	•Rush University Medical Center •Harvard School of Public Health •Brigham and Women's Hospital •National Institute on Aging (NIA)	•Other •NIH	Study Start: January 2017 Primary Completion: December 2020 Study Completion: March 2021 First Received: June 23, 2016 Last Updated: January 13, 2017 Last Verified: January 2017 Results First Received: No Study Results Posted

27	NCT02372773	Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects	Title Acronym: LEFFTDS Other Ids: •14-007532 •U01AG045390	Recruiting	•Familial Frontotemporal Dementia		Study Types: Observational Phase: Study Designs: •Observational Model: Family-Based •Time Perspective: Prospective Outcome Measures: •Rate of decline in traditional measures of clinical (neuropsychological and behavioral composites) function and cortical volume on structural MRI in the symptomatic phase of familial FTD •Rate of decline in traditional measures of clinical (neuropsychological and behavioral composites) function and cortical volume on structural MRI in the asymptomatic phase of familial FTD •Value of novel imaging and clinical measures for characterizing asymptomatic familial FTD subjects, and factors predicting clinical rates of progression in each group. •Genetic and biofluid factors that modify rates of clinical and neuroimaging decline in the asymptomatic and symptomatic phases of familial FTD.	Enrollment: 300 Age: 18 Years to 90 Years (Adult, Senior) Sex: All	•Mayo Clinic •National Institute on Aging (NIA) •National Institute of Neurological Disorders and Stroke (NINDS)	•Other •NIH	Study Start: April 2015 Primary Completion: April 2019 Study Completion: April 2019 First Received: February 20, 2015 Last Updated: March 21, 2017 Last Verified: March 2017 Results First Received: No Study Results Posted
28	NCT03123224	The COACH Project: Combined Online Assistance for Caregiver Health	Title Acronym: COACH Other Ids: FAI0003AGG	Recruiting	•Traumas, Brain •Alzheimer Disease •Dementia •Head Injury •Concussion, Brain •TBI	•Behavioral: Combined Aerobic and Resistance Exercise + Caregiver Skills Training •Behavioral: Stretching Balance and Flexibility + Caregiver Skills Training	Study Types: Interventional Phase: Study Designs: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures: Caregiver Burden using Zarit Burden Inventory	Enrollment: 200 Age: 18 Years to 85 Years (Adult, Senior) Sex: All	•Palo Alto Veterans Institute for Research •United States Department of Defense	•Other •U.S. Fed	Study Start: August 2015 Primary Completion: July 2018 Study Completion: July 2018 First Received: April 3, 2017 Last Updated: April 20, 2017 Last Verified: April 2017 Results First Received: No Study Results Posted
29	NCT02640339	Retinal Abnormalities as Biomarker of Disease Progression and Early Diagnosis of Parkinson Disease	Title Acronym: Other Ids: 15-01391	Recruiting	•Parkinson Disease •Multiple System Atrophy •REM Sleep Behavior Disorder •Pure Autonomic Failure •Dementia With Lewy Bodies		Study Types: Observational Phase: Study Designs: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: •Retinal nerve fiber layer (RNFL) thickness •Retinal ganglion cell layer (GCL) thickness •• Visual Acuity •• Color Discrimination •• Pupillometry •• Videonystagmography	Enrollment: 170 Age: 18 Years and older (Adult, Senior) Sex: All	•New York University School of Medicine •Michael J. Fox Foundation for Parkinson's Research	•Other	Study Start: February 2016 Primary Completion: January 2019 Study Completion: January 2019 First Received: December 22, 2015 Last Updated: July 20, 2017 Last Verified: July 2017 Results First Received: No Study Results Posted

30	NCT03244488	Mental Ability Challenge Study in Adults With and Without HIV	Title Acronym Other Ids 150929	Recruiting	•HIV-1-infection •Aging, Premature •Cognitive Impairment •Memory Impairment •HIV-Associated Cognitive Motor Complex	•Drug: Scopolamine Injectable Product •Drug: Mecamylamine Pill	Study Types Observational Phase Study Designs •Observational Model: Case-Crossover •Time Perspective: Cross-Sectional Outcome Measures •Cognitive Outcome - Lower verbal memory score •Age and HIV-Status Interaction - Slower CRTreaction time	Enrollment 30 Age 35 Years and older (Adult, Senior) Sex All	•Vanderbilt University Medical Center	•Other	Study Start December 2015 Primary Completion May 2018 Study Completion May 2018 First Received July 27, 2017 Last Updated August 4, 2017 Last Verified August 2017 Results First Received No Study Results Posted

31	NCT02569398	An Efficacy and Safety Study of JNJ-54861911 in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia	Title Acronym: EARLY Other Ids: •CR107373 •2015-000948-42 •54861911ALZ2003	Recruiting	•Asymptomatic Amyloid-positive	•Drug: JNJ-54861911, 5 mg •Drug: JNJ-54861911, 25 mg •Drug: Placebo	Study Types: Interventional Phase: •Phase 2 •Phase 3 Study Designs: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double (Participant, Investigator) •Primary Purpose: Treatment Outcome Measures: •Change from Baseline in Preclinical Alzheimer Cognitive Composite (PACC) to Month 54 •Change from Baseline in Cognitive Function Index (CFI) to Month 54 •Change from Baseline in Alzheimer's Disease Cooperative Study - Activities of Daily Living - Prevention Instrument (ADCS-ADLPI) Total Score to Month 54 •Change from Baseline in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Total Scale Score to Month 51 •Change from Baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score to Month 54 •Change from Baseline in Neuropsychological Assessment Battery Daily Living Tests (NABDLTs) Score to Month 54 •Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) •Trough Plasma Concentration (Ctrough) of JNJ-54861911 •Area Under the Plasma Concentration-Time Curve From 0 to tau Hours After Dosing (AUCtau) •Change in mean Cerebral Fibrillar Amyloid Accumulation •Change From Baseline of Neurodegeneration by Assessing Changes in Imaging Biomarkers	Enrollment: 1650 Age: 60 Years to 85 Years (Adult, Senior) Sex: All	•Janssen Research & Development, LLC	•Industry	Study Start: November 23, 2015 Primary Completion: April 10, 2024 Study Completion: April 10, 2024 First Received: October 5, 2015 Last Updated: August 25, 2017 Last Verified: August 2017 Results First Received: No Study Results Posted

32	NCT03153371	Early-onset Alzheimer's Disease Phenotypes: Neuropsychology and Neural Networks	Title Acronym: EOAD-Subtype Other Ids: •1RF1AG050967 •UCLA IRB#16-000496 •1RF1AG050967-01A1	Recruiting	•Alzheimer Disease, Early Onset •Alzheimer Disease •Alzheimer Disease, Late Onset •Dementia, Alzheimer Type •Logopenic Progressive Aphasia •Primary Progressive Aphasia •Visuospatial/ Perceptual Abilities •Posterior Cortical Atrophy •Executive Dysfunction •Corticobasal Degeneration •Ideomotor Apraxia		Study Types: Observational Phase: Study Designs: •Observational Model: Case-Control •Time Perspective: Prospective Outcome Measures: •Alzheimer's disease Subtype •Change in overall Neurological profile •Brain atrophy in MRI - Magnetic Resonance Imaging of the brain •Change in overall Neuropsychological profile	Enrollment: 180 Age: 40 Years to 85 Years (Adult, Senior) Sex: All	•University of California, Los Angeles •National Institute on Aging (NIA) •University of Southern California	•Other •NIH	Study Start: April 4, 2016 Primary Completion: March 31, 2021 Study Completion: March 31, 2022 First Received: April 27, 2017 Last Updated: May 11, 2017 Last Verified: May 2017 Results First Received: No Study Results Posted
33	NCT03135327	Clinical Applications of Advanced Ophthalmic Imaging	Title Acronym: Other Ids: 20070492	Recruiting	•Multiple Sclerosis •Dry Eye Syndromes •Diabetic Retinopathy •Presbyopia •Myopia •Dementia	•Other: No intervention	Study Types: Observational Phase: Study Designs: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: •Retinal microstructure using OCT. •Retinal vasculature by optical coherence tomography angiography (OCTA) •Conjunctival vasculature by functional slit-lamp (FSLB) •Corneal epithelial thickness and tear film thickness •Retinal blood flow velocity by retinal function imager (RFI) •Conjunctival blood flow velocity by functional slit-lamp (FSLB)	Enrollment: 5000 Age: Child, Adult, Senior Sex: All	•University of Miami	•Other	Study Start: January 1, 2007 Primary Completion: December 31, 2020 Study Completion: December 31, 2020 First Received: April 24, 2017 Last Updated: April 28, 2017 Last Verified: April 2017 Results First Received: No Study Results Posted
34	NCT01459302	Genetic Study of Familial and Sporadic ALS/ Motor Neuron Disease, Miyoshi Myopathy and Other Neuromuscular Disorders	Title Acronym: Other Ids: •H-13019 •5RC2NS070342-02	Recruiting	•Amyotrophic Lateral Sclerosis •Frontotemporal Dementia •PLS •Motor Neuron Disease •Lou Gehrigs Disease •Familial Disease •Amyotrophic Lateral Sclerosis, Sporadic •Muscular Dystrophy •Miyoshi Myopathy		Study Types: Observational Phase: Study Designs: •Observational Model: Other •Time Perspective: Prospective Outcome Measures: identification of new genes that may contribute to ALS	Enrollment: 6000 Age: Child, Adult, Senior Sex: All	•University of Massachusetts Worcester •National Institute of Neurological Disorders and Stroke (NINDS)	•Other •NIH	Study Start: January 2009 Primary Completion: October 2018 Study Completion: October 2018 First Received: October 21, 2011 Last Updated: August 30, 2017 Last Verified: August 2017 Results First Received: No Study Results Posted

35	NCT02606422	tDCS Intervention in Primary Progressive Aphasia	Title Acronym Other Ids NIH/NIDCD R01DC014475	Recruiting	•Primary Progressive Aphasia •MCI •FTD	•Device: Active tDCS plus Speech-Language Therapy •Device: Sham plus Speech-Language Therapy	Study Types Interventional Phase Study Designs •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures •Change in oral naming (trained items) •Change in written naming (trained items) •Change in oral naming (untrained items) •Change in written naming (untrained items) •Change in other language and cognitive task performances (global cognitive changes) •Changes in functional connectivity	Enrollment 70 Age 50 Years to 90 Years (Adult, Senior) Sex All	•Johns Hopkins University	•Other	Study Start April 2013 Primary Completion April 2020 Study Completion May 2020 First Received November 11, 2015 Last Updated May 4, 2016 Last Verified May 2016 Results First Received No Study Results Posted
36	NCT01421420	Alzheimer's Disease Core Center	Title Acronym ADCC Other Ids P30AG019610	Recruiting	•Alzheimer's Disease •Mild Cognitive Impairment •Age-Related Memory Disorders		Study Types Observational Phase Study Designs •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures •Neuropsychological Test Scores •Neurological Exam •Brain Tissue	Enrollment 900 Age 50 Years and older (Adult, Senior) Sex All	•University of Arizona •Banner Health •Barrow Neurological Foundation •Mayo Clinic •National Institute on Aging (NIA) •National Institutes of Health (NIH)	•Other •NIH	Study Start July 2001 Primary Completion December 2024 Study Completion July 2025 First Received July 25, 2011 Last Updated June 10, 2015 Last Verified January 2015 Results First Received No Study Results Posted
37	NCT02798185	The DIAGNOSE-CTE Research Project	Title Acronym DIAGNOSE-CTE Other Ids •H-34799 •U01NS093334	Recruiting	•Chronic Traumatic Encephalopathy		Study Types Observational Phase Study Designs •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures •Neuroimaging Positron Emission Tomography for Amyloid Biomarker •Fluid Biomarkers •Neuropsychiatric and Neurocognitive Tests •Neurological Evaluation •Magnetic Resonance Imagining Biomarkers •Neuroimaging Positron Emission Tomography for Tau Biomarker •Magnetic Resonance Spectroscopy Biomarkers	Enrollment 240 Age 45 Years to 74 Years (Adult, Senior) Sex Male	•Boston University •Mayo Clinic •Banner Health •Brigham and Women's Hospital •New York University Langone Medical Center •Lou Ruvo Center for Brain Health-Cleveland Clinic •National Institute of Neurological Disorders and Stroke (NINDS)	•Other •NIH	Study Start August 2016 Primary Completion July 2023 Study Completion July 2023 First Received May 20, 2016 Last Updated August 3, 2017 Last Verified August 2017 Results First Received No Study Results Posted

38	NCT02120235	Investigating Lysosomal Storage Diseases in Minority Groups	Title Acronym Other Ids 14-CFCT-11	Recruiting	•Lysosomal Storage Disorders •Gaucher Disease •Fabry Disease •Pompe Disease •Niemann-Pick Disease		Study Types Observational Phase Study Designs •Observational Model: Other •Time Perspective: Other Outcome Measures Number of patients identified with lysosomal storage disorders	Enrollment 20000 Age up to 100 Years (Child, Adult, Senior) Sex All	•O & O Alpan LLC	•Other	Study Start February 2014 Primary Completion February 2018 Study Completion December 2018 First Received April 17, 2014 Last Updated April 3, 2017 Last Verified April 2017 Results First Received No Study Results Posted
39	NCT03279523	F 18 T807 PET (Positron Emission Tomograph)Scan for HIV Infected & Uninfected	Title Acronym Other Ids IND 123119 Protocol G	Recruiting	•Alzheimer Disease •HIV	•Drug: F 18 T807	Study Types Interventional Phase Phase 2 Study Designs •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Diagnostic Outcome Measures •Perform human in vivo tau imaging using F 18 T807 in 30 older (# 50 years old) HIV + participants and 30 HIV- controls. •: Correlate regional quantitative T807 binding potentials (BPs) with cognitive impairment, as documented by neuropsychological performance tests, in HIV+ and HIV- individuals.	Enrollment 60 Age 50 Years and older (Adult, Senior) Sex All	•Washington University School of Medicine	•Other	Study Start May 2016 Primary Completion May 2021 Study Completion November 2021 First Received May 3, 2016 Last Updated September 14, 2017 Last Verified September 2017 Results First Received No Study Results Posted
40	NCT02365922	Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)	Title Acronym ARTFL Other Ids •ARTFL8101 •1U54NS092089-01	Recruiting	•FTLD •Progressive Supranuclear Palsy (PSP) •Frontotemporal Dementia (FTD) •Corticobasal Degeneration (CBD) •PPA Syndrome •Behavioral Variant Frontotemporal Dementia (bvFTD) •Semantic Variant Primary Progressive Aphasia (svPPA) •Nonfluent Variant Primary Progressive Aphasia (nfvPPA) •FTD With Amyotrophic Lateral Sclerosis (FTD/ALS) •Amyotrophic Lateral Sclerosis (ALS) •Oligosymptomatic PSP (oPSP) •Corticobasal Syndrome (CBS)		Study Types Observational Phase Study Designs •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures •Scores of UDS FTLD Module Tests •Progressive Supranuclear Palsy Rating Scale (PSPRS) •Neuroimaging	Enrollment 1560 Age 18 Years to 85 Years (Adult, Senior) Sex All	•University of California, San Francisco •National Center for Advancing Translational Science (NCATS) •National Institute of Neurological Disorders and Stroke (NINDS) •The Bluefield Project •Tau Consortium	•Other •NIH	Study Start September 2014 Primary Completion September 2020 Study Completion February 2021 First Received February 11, 2015 Last Updated August 23, 2017 Last Verified August 2017 Results First Received No Study Results Posted

41	NCT02327845	Phenotype, Genotype & Biomarkers in ALS and Related Disorders	Title Acronym Other Ids U54NS092091	Recruiting	•Amyotrophic Lateral Sclerosis •Frontotemporal Dementia •Primary Lateral Sclerosis •Hereditary Spastic Paraplegia •Progressive Muscular Atrophy •Multisystem Proteinopathy		Study Types Observational Phase Study Designs •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures •Phenotypic correlates of genotype •Genetic determinants of phenotype	Enrollment 700 Age Child, Adult, Senior Sex All	•University of Miami •National Institute of Neurological Disorders and Stroke (NINDS) •National Center for Advancing Translational Science (NCATS) •St. Jude Children's Research Hospital •ALS Association	•Other •NIH	Study Start April 2015 Primary Completion August 2019 Study Completion August 2019 First Received December 24, 2014 Last Updated June 30, 2017 Last Verified June 2017 Results First Received No Study Results Posted
42	NCT02266563	Amyloid and Tauopathy PET Imaging in Acute and Chronic Traumatic Brain Injury	Title Acronym Other Ids GCO 14-0732	Recruiting	•Traumatic Brain Injury •Chronic Traumatic Encephalopathy •Mild Cognitive Impairment	•Drug: Amyvid PET Scan •Drug: T807 PET scan	Study Types Observational Phase Study Designs •Observational Model: Case Control •Time Perspective: Cross-Sectional Outcome Measures •Uptake of [18F]T807 in the brain •Uptake of [18F]AV-45 in the brain •Neuropsychological data composite score	Enrollment 50 Age 40 Years to 85 Years (Adult, Senior) Sex Male	•Samuel Gandy •Icahn School of Medicine at Mount Sinai	•Other	Study Start January 2015 Primary Completion December 2017 Study Completion December 2017 First Received October 13, 2014 Last Updated January 9, 2017 Last Verified January 2017 Results First Received No Study Results Posted
43	NCT03259958	A Bioequivalence Study of Corplex™ Donepezil Transdermal Delivery System Compared to Oral Aricept®	Title Acronym Other Ids P-16010	Recruiting	•Alzheimer's Disease	•Drug: Donepezil TDS •Drug: Aricept Oral Product	Study Types Interventional Phase Phase 1 Study Designs •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures •PK, AUC •PK, Cmax •Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 •PI assessment of local skin irritation response to TDS •PI assessment of TDS Adhesion	Enrollment 60 Age 30 Years and older (Adult, Senior) Sex All	•Corium International Inc.	•Industry	Study Start September 2017 Primary Completion April 2018 Study Completion August 2018 First Received August 21, 2017 Last Updated August 24, 2017 Last Verified August 2017 Results First Received No Study Results Posted
44	NCT03233646	OCTA in Mild Cognitive Impairment and Alzheimer's Disease	Title Acronym Other Ids Pro00082598	Recruiting	•Alzheimer Disease •Mild Cognitive Impairment •Retinal Vascular	•Device: Retinal Imaging	Study Types Interventional Phase Study Designs •Allocation: Non-Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Screening Outcome Measures •Foveal avascular zone •Vessel Density •Choroidal Thickness	Enrollment 200 Age 18 Years and older (Adult, Senior) Sex All	•Duke University	•Other	Study Start July 20, 2017 Primary Completion July 2018 Study Completion July 2018 First Received July 26, 2017 Last Updated July 26, 2017 Last Verified July 2017 Results First Received No Study Results Posted

45	NCT03149380	Effectiveness of Alzheimer's Universe (Www.Alzu.Org) on Knowledge and Behavior	Title Acronym Other Ids 1311014539	Recruiting	•Alzheimer Disease •Alzheimer Disease, Late Onset •Memory Loss •Patient Education as Topic	•Behavioral: Web-based educational recommendations	Study Types Interventional Phase Study Designs •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Prevention Outcome Measures •Willingness to Engage in AD Preventative behaviors •Participant Satisfaction	Enrollment 10000 Age 21 Years and older (Adult, Senior) Sex All	•Weill Medical College of Cornell University	•Other	Study Start January 2017 Primary Completion December 2018 Study Completion October 2024 First Received January 13, 2017 Last Updated August 28, 2017 Last Verified August 2017 Results First Received No Study Results Posted
46	NCT03140865	Wake Forest Alzheimer's Disease Clinical Core	Title Acronym ADCC Other Ids IRB00025540	Recruiting	•Alzheimer's Disease •Mild Cognitive Impairment •Prediabetic State		Study Types Observational Phase Study Designs •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures •Change in performance on cognitive measures. •Change in biomarker levels in cerebrospinal fluid (CSF). •Change in brain volumes on magnetic resonance imaging (MRI).	Enrollment 500 Age 55 Years and older (Adult, Senior) Sex All	•Wake Forest University Health Sciences	•Other	Study Start January 2014 Primary Completion January 2021 Study Completion June 2021 First Received December 19, 2014 Last Updated May 3, 2017 Last Verified May 2017 Results First Received No Study Results Posted
47	NCT03136679	Discovery of Novel Biomarkers That Will Lead to the Early Detection of Alzheimer's Disease	Title Acronym BVB Other Ids 017-039	Recruiting	•Mild Cognitive Impairment •Alzheimer Disease		Study Types Observational Phase Study Designs •Observational Model: Case-Control •Time Perspective: Prospective Outcome Measures Discovery of novel biomarkers that will lead to the early detection of Alzheimer's disease.	Enrollment 220 Age 40 Years and older (Adult, Senior) Sex All	•Baylor Research Institute	•Other	Study Start March 22, 2017 Primary Completion April 30, 2019 Study Completion December 31, 2019 First Received April 28, 2017 Last Updated May 2, 2017 Last Verified May 2017 Results First Received No Study Results Posted
48	NCT03124550	Development of An Exergame for Caregivers of Family Members With Alzheimer's Disease	Title Acronym Other Ids •Exergame #17065 •5P30AG048785	Recruiting	•Sedentary Lifestyle •Stress, Psychological	•Behavioral: Exergame Experience	Study Types Interventional Phase Study Designs •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Supportive Care Outcome Measures •Number of steps •Exercise Intensity •Exercise self-efficacy •Number of social contacts	Enrollment 20 Age Child, Adult, Senior Sex All	•Brandeis University •National Institute on Aging (NIA)	•Other •NIH	Study Start May 11, 2017 Primary Completion June 2019 Study Completion June 2020 First Received April 13, 2017 Last Updated May 11, 2017 Last Verified May 2017 Results First Received No Study Results Posted
49	NCT03080051	Evaluation of [18F]MNI-952 as a Potential PET Radioligand for Imaging Tau Protein in the Brain	Title Acronym Other Ids [18F]MNI-952	Recruiting	•Progressive Supranuclear Palsy •Alzheimer Disease •Healthy Volunteers	•Drug: [18F]MNI-952 •Drug: [18F]Florbetapir	Study Types Interventional Phase Early Phase 1 Study Designs •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Other Outcome Measures Tracer uptake will be evaluated in regions of interest for analysis of regional [18F]MNI-952 binding/uptake and expressed in SUV by using established methods for normalization for 2 PSP, 2 AD, and 2 HV subjects.	Enrollment 6 Age 18 Years to 90 Years (Adult, Senior) Sex All	•Molecular NeuroImaging	•Other	Study Start August 2016 Primary Completion August 2017 Study Completion August 2017 First Received January 12, 2017 Last Updated March 14, 2017 Last Verified March 2017 Results First Received No Study Results Posted

50	NCT03071224	Phase 1 Test-retest Evaluation of [18F]MK-6240 PET as an Imaging Marker for Neurofibrillary Tangles in the Brain	Title Acronym Other Ids [18F] MNI-946	Recruiting	•Alzheimer Disease •Healthy Volunteers	•Drug: [18F] MNI-946 •Drug: [18F]Florbetapir	Study Types Interventional Phase Early Phase 1 Study Designs •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Other Outcome Measures Tracer uptake will be evaluated in regions of interest for analysis of regional [18F]MNI-946 binding/uptake and expressed in SUV by using established methods for normalization for 12 AD and 3 HV subjects.	Enrollment 15 Age 18 Years to 80 Years (Adult, Senior) Sex All	•Molecular NeuroImaging	•Other	Study Start June 2016 Primary Completion June 2017 Study Completion June 2017 First Received February 28, 2017 Last Updated February 28, 2017 Last Verified February 2017 Results First Received No Study Results Posted
51	NCT03069391	The Interactive Physical and Cognitive Exercise System	Title Acronym iPACES™ Other Ids •16028 •1R41AG053120-01	Recruiting	•Alzheimer Disease, Early Onset •MCI •Aging •Mild Cognitive Impairment •Neurocognitive Disorder •Cognitive Impairment •Cognitive Change	•Behavioral: physical exercise alone (PES) first •Device: cognitive exercise alone (iCE) first •Device: interactive Physical and Cognitive Exercise (iPACES™)	Study Types Interventional Phase Study Designs •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: None (Open Label) •Primary Purpose: Treatment Outcome Measures •executive function composite score •brain-derived neurotrophic factor (BDNF) •Sit-Stand Test	Enrollment 100 Age 50 Years and older (Adult, Senior) Sex All	•Union College, New York •1st Playable •Albany Medical College •Skidmore College •University of Illinois at Urbana-Champaign •National Institute on Aging (NIA)	•Other •NIH	Study Start March 4, 2017 Primary Completion June 30, 2020 Study Completion June 30, 2020 First Received February 7, 2017 Last Updated February 27, 2017 Last Verified February 2017 Results First Received No Study Results Posted
52	NCT03058965	Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain	Title Acronym Other Ids [18F]MNI-958	Recruiting	•Alzheimer Disease •Healthy Volunteers •Progressive Supranuclear Palsy	•Drug: [18F]MNI-958 •Drug: [18F]Florbetapir •Drug: DaTscan	Study Types Interventional Phase Early Phase 1 Study Designs •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Other Outcome Measures Tracer uptake will be evaluated in regions of interest for analysis of regional [18F]MNI-958 binding/uptake and expressed in SUV by using established methods for normalization for 3 AD, 3 PSP, and 3 HV subjects.	Enrollment 9 Age 50 Years to 90 Years (Adult, Senior) Sex All	•Molecular NeuroImaging	•Other	Study Start November 2016 Primary Completion November 2017 Study Completion November 2017 First Received January 12, 2017 Last Updated March 15, 2017 Last Verified March 2017 Results First Received No Study Results Posted

53	NCT03049501	Caring for the Caregiver Network	Title Acronym Other Ids •20130460 •R01NR014434	Recruiting	•Caregivers of Alzheimer's Disease or Memory Problem Patients	•Behavioral: Caregiving condition •Behavioral: Nutrition condition	Study Types: Interventional Phase: Study Designs: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double (Investigator, Outcomes Assessor) •Primary Purpose: Supportive Care Outcome Measures: •Decrease in depression score as measured by CES-D •Decrease in caregiving burden as measured by Burden Inventory •Increase in caregiver's self report of Self-care •Improve in caregiver's self-report of Physical health •Improve caregiver's Self-efficacy •Improve positive aspects of caregiving	Enrollment: 240 Age: 18 Years and older (Adult, Senior) Sex: All	•University of Miami •National Institute of Nursing Research (NINR)	•Other •NIH	Study Start: July 2013 Primary Completion: December 2017 Study Completion: March 2018 First Received: February 8, 2017 Last Updated: February 8, 2017 Last Verified: February 2017 Results First Received: No Study Results Posted
54	NCT02928211	Aftobetin-HCl and Fluorescence Detection Measured by Sapphire II to Determine the Number and Timing of Administrations	Title Acronym Other Ids: PRT-0036	Recruiting	•Mild Cognitive Impairment •Alzheimer's Disease	•Device: Sapphire II •Drug: Aftobetin-HCl •Radiation: Positron Emission Tomography	Study Types: Interventional Phase: Phase 1 Study Designs: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Diagnostic Outcome Measures: •Paired pre-ligand and post ligand fluorescent uptake values (FUV) •Determination of success (yes or no) •The overall diagnostic precision for each combination of Aftobetin-HCl administrations and Fluorescent Uptake Value (FUV) •Estimates of sensitivity and specificity of MCI and mild AD subjects compared to cognitively normal subjects •Safety of Sapphire II procedure as determined by instances of Adverse Events •Characterization of maximal fluorescence after 1, or potentially 3, ointment administrations •Intra-class correlation of the repeatability of the Sapphire II measurements to verify the system's reliability for reproducible results •Correlation of FUV to PET amyloid status	Enrollment: 105 Age: 25 Years to 90 Years (Adult, Senior) Sex: All	•Cognoptix, Inc.	•Industry	Study Start: July 2016 Primary Completion: March 2018 Study Completion: April 2018 First Received: September 19, 2016 Last Updated: July 26, 2017 Last Verified: July 2017 Results First Received: No Study Results Posted

55	NCT02921672	Feasibility Trial of a Mediterranean Diet Pattern to Prevent Cognitive Decline	Title Acronym Other Ids •STUDY00003894 •P30AG035982	Recruiting	•Alzheimer's Disease •Cognitive Impairment	•Other: Mediterranean Diet	Study Types Interventional Phase Study Designs •Allocation: Non-Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Prevention Outcome Measures Number of participants completing the study	Enrollment 30 Age 65 Years and older (Adult, Senior) Sex All	•University of Kansas Medical Center •National Institute on Aging (NIA)	•Other •NIH	Study Start March 2016 Primary Completion June 2018 Study Completion December 2018 First Received September 29, 2016 Last Updated August 11, 2017 Last Verified August 2017 Results First Received No Study Results Posted
56	NCT02884492	Imaging Tau in Alzheimer's Disease and Normal Aging	Title Acronym Other Ids •AAAQ7868 •1K23AG052633-01	Recruiting	•Alzheimer's Disease	•Drug: 18F-THK-5351 •Procedure: Lumbar Puncture (optional)	Study Types Interventional Phase Phase 2 Study Designs •Allocation: Non-Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Diagnostic Outcome Measures •18F-THK-5351 binding (standardized uptake value ratio) •Cerebral spinal fluid (CSF) concentration of amyloid, tau, and inflammatory markers	Enrollment 60 Age 60 Years and older (Adult, Senior) Sex All	•William Charles Kreisl •National Institute on Aging (NIA) •Columbia University	•Other •NIH	Study Start July 2016 Primary Completion June 2021 Study Completion June 2021 First Received August 25, 2016 Last Updated December 7, 2016 Last Verified December 2016 Results First Received No Study Results Posted
57	NCT02875496	Reference Database & Longitudinal Registry of the Normal and Pathological Aging Brain	Title Acronym (BNA™) Other Ids ELM-26	Recruiting	•Early Onset Alzheimer Disease •Mild Cognitive Impairment •Depression •Aging		Study Types Observational Phase Study Designs •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures Developing a BNA database for healthy aging population.	Enrollment 2000 Age 50 Years to 85 Years (Adult, Senior) Sex All	•ElMindA Ltd	•Industry	Study Start August 2016 Primary Completion August 2022 Study Completion December 2022 First Received August 4, 2016 Last Updated August 17, 2016 Last Verified August 2016 Results First Received No Study Results Posted
58	NCT02835716	Pre-Clinical (Alzheimers) Diagnosis PCD = Optimum Outcomes OO	Title Acronym PCD=OOALZ Other Ids PCD=OO ALZ	Recruiting	•Alzheimer Disease	•Drug: roflumilast •Biological: ustekinumab	Study Types Observational Phase Study Designs •Observational Model: Case-Only •Time Perspective: Prospective Outcome Measures Number of Participants who Develop Cognitive Decline	Enrollment 150 Age 50 Years to 75 Years (Adult, Senior) Sex All	•Millennium Magnetic Technologies, LLC	•Industry	Study Start September 2016 Primary Completion September 2019 Study Completion September 2020 First Received July 10, 2016 Last Updated September 10, 2016 Last Verified September 2016 Results First Received No Study Results Posted

59	NCT02769065	Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants	Title Acronym Other Ids: •TAK-071-1001 •U1111-1176-7435	Recruiting	•Alzheimer Disease •Healthy Volunteers	•Drug: TAK-071 •Drug: Donepezil •Drug: TAK-071 Placebo •Drug: TAK-071 •Drug: Donepezil Placebo	Study Types: Interventional Phase: Phase 1 Study Designs: •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: Double (Participant, Investigator) •Primary Purpose: Treatment Outcome Measures: •Percentage of Participants who Experience at Least One Treatment-Emergent Adverse Event (TEAE) •Percentage of Participants who Meet the Markedly Abnormal Criteria for Clinical Laboratory Tests at Least Once Post-dose •Percentage of Participants who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post-dose •Percentage of Participants who Meet the Markedly Abnormal Criteria for 12-lead ECG Parameters at Least Once Post-dose •Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-071 •Cmax: Maximum Observed Plasma Concentration for TAK-071 •AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Post-dose for TAK-071 •AUC#: Area Under the Plasma Concentration-time Curve from Time 0 to Infinity for TAK-071 •AUC#: Area Under the Plasma Concentration-time Curve from Time 0 to tau Over the Dosing Interval for TAK-071 •Terminal Phase Elimination Half-life (T1/2) for TAK-071 •Apparent Clearance (CL/F) for TAK-071 •Accumulation Ratio Based on AUC (Rac[AUC] for TAK-071) •Accumulation Ratio Based on Plasma Cmax (Rac[Cmax]) for TAK-071 •Amount of Drug Excreted in Urine From Time 0 to Time t (Ae[t]) for TAK-071 •Fraction of Administered Dose of Drug Excreted in Urine From Time 0 to Time t (f[e,t]) for TAK-071 •Renal Clearance (CL[R]) for TAK-071 •CSF Cmax: Maximum Observed Concentration in Cerebrospinal Fluid (CSF) for TAK-071	Enrollment: 186 Age: 18 Years to 90 Years (Adult, Senior) Sex: All	•Takeda	•Industry	Study Start: May 5, 2016 Primary Completion: March 13, 2018 Study Completion: March 13, 2018 First Received: May 10, 2016 Last Updated: August 2, 2017 Last Verified: August 2017 Results First Received: No Study Results Posted

60	NCT02719327	Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid	Title Acronym: BRAVE-EPA Other Ids: •CLNA-001-15S •CX001261	Recruiting	•Alzheimer's Disease	•Drug: icosapent ethyl (IPE) •Other: gel cap placebo	Study Types: Interventional Phase: •Phase 2 •Phase 3 Study Designs: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Prevention Outcome Measures: •Regional cerebral blood flow using arterial spin-labeling MRI •Cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease •cognitive performance	Enrollment: 150 Age: 50 Years to 75 Years (Adult, Senior) Sex: All	•VA Office of Research and Development •University of Wisconsin, Madison	•U.S. Fed •Other	Study Start: December 1, 2016 Primary Completion: November 30, 2021 Study Completion: November 30, 2021 First Received: March 21, 2016 Last Updated: July 14, 2017 Last Verified: July 2017 Results First Received: No Study Results Posted
61	NCT02621606	[11C]MK-6884 Positron Emission Tomography (PET) Tracer Validation Trial (MK-6884-001)	Title Acronym: Other Ids: •6884-001 •2015-001631-20	Recruiting	•Alzheimer's Disease	•Drug: [11C]MK-6884	Study Types: Interventional Phase: Phase 1 Study Designs: •Allocation: Non-Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Other Outcome Measures: •Number of Participants With Adverse Events (AEs) •Number of Participants Who Discontinued Study Due to an AE •Effective Dose of [11C]MK-6884 (Part I) •Organ Effective Dose of [11C]MK-6884 (Part I) •Volume of Distribution (VT) or Surrogate (e.g., Non-displaceable Binding Potential [BPND]) of [11C]MK-6884 in Brain Regions of Interest (Part II) •Intra-subject T-RT Variability of [11C]MK-6884 in Brain Regions of Interest (Part II) •BPND or Surrogate (e.g., Standardized Uptake Value Ratio [SUVR]) of [11C]MK-6884 in Brain Regions of Interest (Part III)	Enrollment: 26 Age: 18 Years to 85 Years (Adult, Senior) Sex: All	•Merck Sharp & Dohme Corp.	•Industry	Study Start: January 8, 2016 Primary Completion: October 6, 2017 Study Completion: October 6, 2017 First Received: November 20, 2015 Last Updated: August 9, 2017 Last Verified: August 2017 Results First Received: No Study Results Posted
62	NCT02612376	Rocky Mountain Alzheimer's Disease Center Longitudinal Biomarker and Clinical Phenotyping Study	Title Acronym: Other Ids: 15-1774	Recruiting	•Alzheimer Disease •Down Syndrome •Mild Cognitive Impairment		Study Types: Observational Phase: Study Designs: •Observational Model: Case Control •Time Perspective: Prospective Outcome Measures: Longitudinal collection of biospecimens and data from participants with MCI, AD, DS, healthy controls, and parents of DS individuals.	Enrollment: 800 Age: 18 Years and older (Adult, Senior) Sex: All	•University of Colorado, Denver	•Other	Study Start: February 2016 Primary Completion: December 2030 Study Completion: December 2030 First Received: November 13, 2015 Last Updated: November 14, 2016 Last Verified: November 2016 Results First Received: No Study Results Posted

63	NCT02380573	Cognitive and Functional Connectivity Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease	Title Acronym: MB2 Other Ids: HSC20150410H	Recruiting	•Mild Cognitive Impairment •MCI •Aging •Alzheimer's Disease •AD	•Drug: Methylene Blue •Drug: FD&C Blue # 2 •Drug: Phenazopyridine hydrochloride	Study Types: Interventional Phase: Phase 2 Study Designs: •Allocation: Randomized •Intervention Model: Single Group Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •Working memory task fMRI •Working memory task response •Episodic memory task fMRI •Episodic memory task response •Sustained attention task fMRI •Sustained attention task reaction time •Neuropsychological battery composite score •Cerebral blood flow fMRI measures	Enrollment: 240 Age: 45 Years to 89 Years (Adult, Senior) Sex: All	•Peter Fox •Texas Alzheimer's Research and Care Consortium (TARCC) •The University of Texas Health Science Center at San Antonio	•Other	Study Start: July 2015 Primary Completion: July 2017 Study Completion: July 2018 First Received: February 24, 2015 Last Updated: July 21, 2016 Last Verified: July 2016 Results First Received: No Study Results Posted
64	NCT02087865	Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease	Title Acronym: Other Ids: NIH AG022304	Recruiting	•Genetic Risk for Alzheimer's Disease	•Drug: donepezil HCL •Drug: Placebo	Study Types: Interventional Phase: Phase 4 Study Designs: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Triple (Participant, Care Provider, Outcomes Assessor) •Primary Purpose: Other Outcome Measures: •Change in BOLD response during functional magnetic resonance imaging •Neuropsychological testing scores	Enrollment: 90 Age: 60 Years to 75 Years (Adult, Senior) Sex: All	•The Cleveland Clinic •National Institute on Aging (NIA)	•Other •NIH	Study Start: May 2014 Primary Completion: April 2018 Study Completion: April 2018 First Received: March 7, 2014 Last Updated: May 17, 2017 Last Verified: May 2017 Results First Received: No Study Results Posted
65	NCT01931644	Be the Bridge Between Researchers and a Cure (GVHD, ALS, Hepatitis B, Alzheimer's Disease, Leukemia, and More)	Title Acronym: Other Ids: SAN-BB-01	Recruiting	•All Diagnosed Health Conditions		Study Types: Observational Phase: Study Designs: •Observational Model: Cohort •Time Perspective: Cross-Sectional Outcome Measures: Biospecimen & Clinical Data Collection	Enrollment: 20000 Age: 18 Years to 100 Years (Adult, Senior) Sex: All	•Sanguine Biosciences	•Industry	Study Start: July 2013 Primary Completion: August 2020 Study Completion: December 2040 First Received: August 23, 2013 Last Updated: March 16, 2016 Last Verified: March 2016 Results First Received: No Study Results Posted
66	NCT01747213	Bisnorcymserine in Healthy Adult Volunteers	Title Acronym: Other Ids: •130034 •13-AG-0034	Recruiting	•Alzheimer's Disease	•Drug: BNC	Study Types: Interventional Phase: Phase 1 Study Designs: •Allocation: Randomized •Intervention Model: Single Group Assignment •Primary Purpose: Treatment Outcome Measures: •Safety and tolerability •Pharmacokinetics	Enrollment: 200 Age: 55 Years and older (Adult, Senior) Sex: All	•National Institute on Aging (NIA) •National Institutes of Health Clinical Center (CC)	•NIH	Study Start: November 15, 2012 Primary Completion: July 1, 2018 Study Completion: July 3, 2018 First Received: December 8, 2012 Last Updated: July 26, 2017 Last Verified: July 17, 2017 Results First Received: No Study Results Posted

67	NCT01297114	Imaging of Cognition, Learning, and Memory in Aging	Title Acronym Other Ids •AAAB0596 •R01AG026158	Recruiting	•Alzheimer's Disease	•Drug: Florbetaben	Study Types Observational Phase Study Designs •Observational Model: Cohort •Time Perspective: Cross-Sectional Outcome Measures Cognition as measured with cognitive evaluations	Enrollment 550 Age 20 Years to 70 Years (Adult, Senior) Sex All	•Yaakov Stern •National Institute on Aging (NIA) •Columbia University	•Other •NIH	Study Start March 2011 Primary Completion December 2017 Study Completion December 2021 First Received February 14, 2011 Last Updated August 24, 2016 Last Verified August 2016 Results First Received No Study Results Posted
68	NCT02831283	Imaging Inflammation in Alzheimer's Disease	Title Acronym Other Ids •AAAO1151 •1K23AG052633-01	Recruiting	•Alzheimer's Disease	•Drug: 11C-PBR28 •Drug: 18F-Florbetaben •Procedure: Lumbar puncture (optional)	Study Types Interventional Phase Phase 2 Study Designs •Allocation: Non-Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Diagnostic Outcome Measures •11C-PBR28 binding (standardized uptake value ratio) •18F-Florbetaben binding (standardized uptake value ratio) •Cerebral spinal fluid (CSF) biomarkers	Enrollment 100 Age 60 Years and older (Adult, Senior) Sex All	•William Charles Kreisl •National Institute on Aging (NIA) •Columbia University	•Other •NIH	Study Start June 2016 Primary Completion June 2021 Study Completion June 2021 First Received July 10, 2016 Last Updated December 7, 2016 Last Verified December 2016 Results First Received No Study Results Posted
69	NCT01860339	Growth and Development of the Striatum in Huntington's Disease	Title Acronym Kids-HD Other Ids •200507759 •4R01NS055903-08	Recruiting	•Huntington's Disease		Study Types Observational Phase Study Designs •Observational Model: Case-Control •Time Perspective: Cross-Sectional Outcome Measures •Volume of brain structures as measured by Magnetic Resonance Imaging (MRI) •Quantitative assessment of cognitive skills and motor skills	Enrollment 400 Age 6 Years to 18 Years (Child, Adult) Sex All	•Peggy C Nopoulos •CHDI Foundation, Inc. •National Institute of Neurological Disorders and Stroke (NINDS) •University of Iowa	•Other •NIH	Study Start July 2005 Primary Completion August 2018 Study Completion First Received May 16, 2013 Last Updated May 31, 2017 Last Verified May 2017 Results First Received No Study Results Posted
70	NCT02761707	Biomarkers in Neural Disorders	Title Acronym Other Ids 827731	Recruiting	•Parkinson's Disease •Alzheimer's Disease •Progressive Supranuclear Palsy •Essential Tremor •Multiple System Atrophy •Drug Induced Parkinson's Disease •Diffuse Lewy Body Disease •Myasthenia Gravis •Spinal Cord Injuries	•Other: Electrical Brainstem Responses •Other: Olfactory Tests •Other: Visual Deprivation •Other: Peripheral Nerve Stimulation	Study Types Observational Phase Study Designs •Observational Model: Case-Control •Time Perspective: Cross-Sectional Outcome Measures •Latency, amplitude, and area under the curve of brainstem reflex response •Score on the University of Pennsylvania Smell Identification Test •Score on the Odor Discrimination/Memory Test •Score on an Odor Detection Threshold Test	Enrollment 440 Age 18 Years to 80 Years (Adult, Senior) Sex All	•University of Pennsylvania •Michael J. Fox Foundation for Parkinson's Research	•Other	Study Start June 2016 Primary Completion June 2022 Study Completion June 2022 First Received April 18, 2016 Last Updated September 7, 2017 Last Verified September 2017 Results First Received No Study Results Posted

71	NCT02649985	Microglial Activation Positron Emission Tomography (PET) Brain Imaging in Multiple Sclerosis and Alzheimer's Disease	Title Acronym Other Ids: 2015P002329	Recruiting	•Multiple Sclerosis •Alzheimer's Disease	•Drug: [F-18]PBR06	Study Types: Interventional Phase: •Phase 1 •Phase 2 Study Designs: •Allocation: Non-Randomized •Intervention Model: Parallel Assignment •Masking: None (Open Label) •Primary Purpose: Diagnostic Outcome Measures: Tissue Volume of Distribution	Enrollment: 50 Age: 18 Years to 70 Years (Adult, Senior) Sex: All	•Brigham and Women's Hospital	•Other	Study Start: January 2016 Primary Completion: June 2017 Study Completion: June 2017 First Received: January 6, 2016 Last Updated: November 8, 2016 Last Verified: November 2016 Results First Received: No Study Results Posted
72	NCT02754830	A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)	Title Acronym Other Ids: •16120 •I8G-MC-LMDA	Recruiting	•Alzheimer's Disease	•Drug: LY3303560 - IV •Drug: Saline Solution - IV •Drug: LY3303560 - SC	Study Types: Interventional Phase: Phase 1 Study Designs: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Double (Participant, Investigator) •Primary Purpose: Basic Science Outcome Measures: •Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration •Pharmacokinetics (Serum): Area Under the Concentration Versus Time Curve from Time 0 to Infinity (AUC[0-#]) of LY3303560 •Pharmacokinetics (Serum): Maximum Drug Concentration (Cmax) of LY3303560 •Pharmacokinetics (Cerebrospinal Fluid): Area Under the Concentration Versus Time Curve (AUC) of LY3303560 •Pharmacokinetics (Cerebrospinal Fluid): Maximum Drug Concentration (Cmax) of LY3303560 •Mean Change from Baseline in QT/QT Corrected (QTc) Interval	Enrollment: 110 Age: 30 Years and older (Adult, Senior) Sex: All	•Eli Lilly and Company	•Industry	Study Start: April 25, 2016 Primary Completion: April 2018 Study Completion: April 2018 First Received: April 26, 2016 Last Updated: August 31, 2017 Last Verified: August 2017 Results First Received: No Study Results Posted
73	NCT02474251	Brain Sleep Clearance of Amyloid-Beta Peptides	Title Acronym: Brain SCRAPs Other Ids: 14-01837	Recruiting	•Obstructive Sleep Apnea •Alzheimer's Disease	•Device: Continuous positive airway pressure device	Study Types: Observational Phase: Study Designs: •Observational Model: Other •Time Perspective: Cross-Sectional Outcome Measures: CSF A#42/A#40 levels	Enrollment: 55 Age: 30 Years to 75 Years (Adult, Senior) Sex: All	•New York University School of Medicine	•Other	Study Start: September 2015 Primary Completion: September 2017 Study Completion: September 2018 First Received: June 15, 2015 Last Updated: August 1, 2017 Last Verified: August 2017 Results First Received: No Study Results Posted

74	NCT01962779	Sleep, Aging and Risk for Alzheimer's Disease	Title Acronym: SARA Other Ids: •12-03068 •R01HL118624	Recruiting	•Sleep Disordered Breathing •Alzheimer's Disease	•Device: Continuous positive airway pressure (CPAP)	Study Types: Interventional Phase: Study Designs: •Allocation: Non-Randomized •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Basic Science Outcome Measures: •Observational. Cerebrospinal fluid (CSF) biomarkers of risk for Alzheimer's disease (AD) in sleep disordered breathing (SDB) subjects. •Observational. Structural MRI hippocampal volume in SDB subjects. •Observational. MRI-ASL vasoreactivity response to CO2 challenge in subjects with SDB •Interventional CPAP Clinical Trial, memory changes after CPAP treatment •Interventional CPAP Clinical Trial, CSF biomarker changes after CPAP treatment •Interventional CPAP Clinical Trial, MRI biomarker changes	Enrollment: 45 Age: 50 Years and older (Adult, Senior) Sex: All	•New York University School of Medicine •National Heart, Lung, and Blood Institute (NHLBI)	•Other •NIH	Study Start: July 2013 Primary Completion: December 2017 Study Completion: December 2017 First Received: August 27, 2013 Last Updated: May 5, 2017 Last Verified: May 2017 Results First Received: No Study Results Posted
75	NCT01713816	Human Brain Antioxidants During Oxidative Stress	Title Acronym: Other Ids: •1208M18321 •R01AG039396	Recruiting	•Oxidative Stress •Alzheimer's Disease •Aging		Study Types: Observational Phase: Study Designs: •Observational Model: Case Control •Time Perspective: Cross-Sectional Outcome Measures: Antioxidant in Alzheimers	Enrollment: 86 Age: 65 Years to 89 Years (Adult, Senior) Sex: All	•University of Minnesota - Clinical and Translational Science Institute •National Institute on Aging (NIA)	•Other •NIH	Study Start: June 2013 Primary Completion: May 2017 Study Completion: December 2017 First Received: October 22, 2012 Last Updated: October 25, 2016 Last Verified: October 2016 Results First Received: No Study Results Posted
76	NCT01498263	Inherited Diseases, Caregiving, and Social Networks	Title Acronym: Other Ids: •120022 •12-HG-0022	Recruiting	•Alzheimer's Disease •Inborn Errors of Metabolism •Mitochondrial Disorders •Undiagnosed Diseases		Study Types: Observational Phase: Study Designs: Time Perspective: Other Outcome Measures: Develop measures of caregiving processes, identify family network characteristics associated with positive adaptation, and investigate the role of perceived AD risk in caregiving and social support processes.	Enrollment: 3100 Age: 18 Years and older (Adult, Senior) Sex: All	•National Human Genome Research Institute (NHGRI) •National Institutes of Health Clinical Center (CC)	•NIH	Study Start: December 5, 2011 Primary Completion: Study Completion: First Received: December 21, 2011 Last Updated: September 12, 2017 Last Verified: September 1, 2017 Results First Received: No Study Results Posted

77	NCT02402426	Brain Health Registry	Title Acronym: BHR Other Ids: 12-09628	Recruiting	•Healthy •Neurodegenerative Disease		Study Types: Observational Phase: Study Designs: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: •Alzheimer's Disease •Neurodegenerative Diseases	Enrollment: 50000 Age: 18 Years and older (Adult, Senior) Sex: All	•University of California, San Francisco	•Other	Study Start: September 2013 Primary Completion: September 2023 Study Completion: September 2028 First Received: August 1, 2013 Last Updated: March 1, 2017 Last Verified: March 2017 Results First Received: No Study Results Posted
78	NCT02507206	A D1 Agonist For Working Memory	Title Acronym: Other Ids: •GCO 11-1279 •5R01MH097799-02	Recruiting	•Schizotypal Personality Disorder •SPD	•Drug: DAR 0-100A •Drug: Placebo	Study Types: Interventional Phase: Phase 2 Study Designs: •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: Double (Participant, Care Provider) •Primary Purpose: Treatment Outcome Measures: The Modified AX-CPT (d')	Enrollment: 120 Age: 18 Years to 65 Years (Adult) Sex: All	•Antonia New •New York State Psychiatric Institute •National Institute of Mental Health (NIMH) •Icahn School of Medicine at Mount Sinai	•Other •NIH	Study Start: April 2013 Primary Completion: February 2018 Study Completion: February 2018 First Received: July 22, 2015 Last Updated: March 23, 2017 Last Verified: March 2017 Results First Received: No Study Results Posted
79	NCT02966145	4-Repeat Tauopathy Neuroimaging Initiative - Cycle 2	Title Acronym: 4RTNI-2 Other Ids: •4RTNI-2 •2R01AG038791-06A1	Recruiting	•Corticobasal Degeneration (CBD) •Corticobasal Syndrome (CBS) •Cortical-basal Ganglionic Degeneration (CBGD) •Progressive Supranuclear Palsy (PSP) •Nonfluent Variant Primary Progressive Aphasia (nfvPPA) •Oligosymptomatic/ Variant Progressive Supranuclear Palsy (o/vPSP)	•Other: Observational Study	Study Types: Observational Phase: Study Designs: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: •Tau-PET Brain Scan •Amyloid-PET Brain Scan •Brain Volume on MRI •Progressive Supranuclear Palsy Rating Scale (PSPRS) •Corticobasal Degeneration Functional Scale (CBDFS) •Eye Movement Function •Retinal Imaging •UDS Neuropsychological Testing Battery, including supplemental FTLD Module	Enrollment: 232 Age: 40 Years to 80 Years (Adult, Senior) Sex: All	•University of California, San Francisco •National Institutes of Health (NIH) •National Institute on Aging (NIA)	•Other •NIH	Study Start: January 2016 Primary Completion: December 2021 Study Completion: December 2021 First Received: November 15, 2016 Last Updated: November 15, 2016 Last Verified: November 2016 Results First Received: No Study Results Posted

80	NCT02844478	Stress-Busting Program and QoL, Bio-markers of Immunity/Stress and Cellular Aging	Title Acronym Other Ids HSC201603009H	Recruiting	•Stress, Psychological •Telomere Shortening •Stress, Physiological	•Behavioral: SBP English •Behavioral: SBP SPANISH	Study Types Interventional Phase Study Designs •Allocation: Non-Randomized •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Supportive Care Outcome Measures •Telomere length •Salivary flow rate •Saliva potential hydrogen (pH) •Salivary protein •Perceived Stress Scale •Center for Epidemiologic Depression (CES-D) •Screen for Caregiver Burden •Salivary alpha Amylase (sAA) •Secretory immunoglobulin A (SIgA) •C Reactive Protein (CRP)	Enrollment 100 Age 18 Years and older (Adult, Senior) Sex All	•The University of Texas Health Science Center at San Antonio •WellMed Charitable Foundation •San Antonio Claude D. Pepper Older Americans Independence Center •The Sam and Ann Barshop Institute for Longevity and Aging Studies •San Antonio Geriatrics Research Education and Clinical Center-GRECC •Caring Companions •Alzheimer's Association	•Other	Study Start September 2016 Primary Completion December 2017 Study Completion December 2017 First Received July 20, 2016 Last Updated September 6, 2017 Last Verified September 2017 Results First Received No Study Results Posted
81	NCT02959489	Risk Evaluation and Education for Alzheimer's Disease - the Study of Communicating Amyloid Neuroimaging (REVEAL-SCAN)	Title Acronym REVEAL-SCAN Other Ids •RF1AG047866 •1RF1AG047866-01A1	Recruiting	•Alzheimer Disease •Amyloid Beta-Peptides •Risk Assessment •Education •Neuropsychological Tests •Neuroimaging	•Behavioral: Alzheimer's Disease Risk Disclosure •Behavioral: Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure	Study Types Interventional Phase Study Designs •Allocation: Randomized •Intervention Model: Crossover Assignment •Masking: None (Open Label) •Primary Purpose: Health Services Research Outcome Measures •Change in baseline neuropsychological performance compared to 6 weeks and 6 months post-disclosure •Change in baseline measure scores on scales and questionnaires of psychological distress compared to 6 weeks and 6 months post-disclosure. •Change in baseline measures of health behaviors compared to 6 weeks and 6 months post-disclosure to determine the type and frequency of behavior changes in response to learning risk information.	Enrollment 270 Age 65 Years to 80 Years (Adult, Senior) Sex All	•Brigham and Women's Hospital •University of Pennsylvania •University of Michigan •Duke University •Boston University •National Institute on Aging (NIA)	•Other •NIH	Study Start November 2016 Primary Completion July 2019 Study Completion July 2019 First Received October 24, 2016 Last Updated December 19, 2016 Last Verified December 2016 Results First Received No Study Results Posted

82	NCT02854033	Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol	Title Acronym Other Ids	ADNI3 •ATRI-001 •U01AG024904	Recruiting	•Mild Cognitive Impairment (MCI) •Alzheimer's Disease (AD)		Study Types Phase Study Designs Outcome Measures	Observational •Observational Model: Cohort •Time Perspective: Prospective •Rate of change in cognition as measured by the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog13) •Rate of change in cognition as measured by the Logical Memory Test I and II •Rate of change in cognition as measured by the Mini-Mental State Examinations (MMSE) •Rate of change in cognition as measured by the Cogstate Brief Battery (CBB) •Rate of change in cognition as measured by the American National Adult Reading Test (ANART) •Rate of change in cognition as measured by the Montreal Cognitive Assessment (MoCA) •Rate of change in cognition as measured by the Rey Auditory Verbal Learning Test •Rate of change in cognition as measured by the Trail Making Test: A and B •Change in tau deposition as measured by 18F-AV-1451 •Change in amyloid deposition as measured by Florbetapir •Change in amyloid deposition as measured by Florbetaben •Rate of conversion to MCI or dementia due to AD •Rates of change of glucose metabolism (FDG-PET) •Change in Cerebral Spinal Fluid (CSF) Tau Biomarkers •Change in brain structure using magnetic resonance imaging (MRI)	Enrollment Age Sex	2000 55 Years to 90 Years (Adult, Senior) All	•University of Southern California •Northern California Institute of Research and Education •National Institute on Aging (NIA) •Alzheimer's Therapeutic Research Institute	•Other •NIH	Study Start Primary Completion Study Completion First Received Last Updated Last Verified Results First Received	October 2016 October 2021 October 2021 July 27, 2016 September 8, 2017 September 2017 No Study Results Posted

83	NCT01687153	A Study of Brain Aging in Vietnam War Veterans	Title Acronym: DOD-ADNI Other Ids: •ADC-044 •W81XWH-12-2-0012 •W81XWH-13-1-0259 •W81XWH-14-1-0462	Recruiting	•Traumatic Brain Injury •Post Traumatic Stress Disorder •Alzheimer's Disease •Mild Cognitive Impairment		Study Types: Observational Phase: Study Designs: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: •Rates of change in brain regions based on neuroimaging •Rates of change in CSF amyloid beta and CSF tau/P tau levels based on biomarkers •Rates of change in neuropsychological measures of memory and general cognitive performance •Correlations within each group (TBI and PTSD) to assess whether baseline levels or rates of atrophy or cognitive decline are associated with severity of TBI or PTSD •Group differences in the patterns of amyloid deposition (from Florbetapir F 18) and brain atrophy •Group differences in white matter integrity as assessed with Diffusion Tension Imaging (DTI) •Rate of change of tau deposition as measured by 18F-AV-1451	Enrollment: 420 Age: 50 Years to 90 Years (Adult, Senior) Sex: All	•University of Southern California •United States Department of Defense •Telemedicine & Advanced Technology Research Center •Northern California Institute of Research and Education •San Francisco Veterans Affairs Medical Center •Alzheimer's Therapeutic Research Institute	•Other •U.S. Fed	Study Start: October 2012 Primary Completion: October 2018 Study Completion: October 2018 First Received: August 31, 2012 Last Updated: September 12, 2017 Last Verified: September 2017 Results First Received: No Study Results Posted
84	NCT02278367	Clinical Evaluation of 18F-AV-1451	Title Acronym: Other Ids: 18F-AV-1451-A14	Recruiting	•Alzheimer's Disease •Traumatic Brain Injury •Depression	•Drug: 18F-AV-1451	Study Types: Interventional Phase: Phase 2 Study Designs: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Diagnostic Outcome Measures: •Safety Assessment: Adverse event frequency related to 18F-AV-1451 administration •Efficacy Assessment: 18F-AV-1451 standard uptake value ratios (SUVRs)	Enrollment: 250 Age: 18 Years and older (Adult, Senior) Sex: All	•Avid Radiopharmac	•Industry	Study Start: December 2014 Primary Completion: December 2017 Study Completion: December 2017 First Received: October 28, 2014 Last Updated: July 19, 2017 Last Verified: July 2017 Results First Received: No Study Results Posted

85	NCT02525198	The Cognitive Ageing Nutrition and Neurogenesis (CANN) Trial	Title Acronym CANN Other Ids R21647	Recruiting	•Mild Cognitive Impairment •Subjective Memory Impairment	•Dietary Supplement: fatty acid/ flavonoid blend •Dietary Supplement: Placebo	Study Types Interventional Phase Study Designs •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Triple (Participant, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures •Number of false positive responses during the picture recognition task of the CDR Computerized Cognitive Assessment System •Hippocampal volume •Gut microflora speciation and metabolism •Association between baseline APOE status and number of false positive responses during the picture recognition task of the CDR Computerized Cognitive Assessment System •Circulating biomarkers of cognition •Circulating biomarkers of cardiovascular health •Language ability on the Boston Naming Test •Visuospatial ability on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Figure Copy test •Attention ability on the Digit Span task •Executive function on the Trail Making Task •Cerebrovascular blood flow •Measurement of blood brain barrier permeability	Enrollment 240 Age 55 Years and older (Adult, Senior) Sex All	•University of East Anglia •Swinburne University of Technology •University of Illinois at Chicago	•Other	Study Start August 2015 Primary Completion April 2018 Study Completion April 2019 First Received May 11, 2015 Last Updated November 17, 2016 Last Verified November 2016 Results First Received No Study Results Posted

86	NCT03056729	Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease	Title Acronym Other Ids 243HV101	Recruiting	•Alzheimer's Disease	•Drug: BIIB076 •Drug: Placebo	Study Types Interventional Phase Phase 1 Study Designs •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Triple (Participant, Care Provider, Investigator) •Primary Purpose: Treatment Outcome Measures •Number of participants that experience Adverse Events (AEs) and Serious Adverse Events (SAEs) •Number of participants with clinically significant laboratory assessment abnormalities •Number of participants with clinically significant vital sign abnormalities •Number of participants with clinically significant physical examination abnormalities •Number of participants with clinically significant neurological examination abnormalities •Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities •Number of participants with clinically significant brain magnetic resonance imaging (MRI) abnormalities •BIIB076 serum pharmacokinetics (PK) concentration levels •PK parameter of BIIB076: Area under the concentration-time curve from time zero to infinity (AUCinf) •PK parameter of BIIB076: Area under the concentration-time curve from time zero to the time of the last measurable sample (AUClast) •PK parameter of BIIB076: Maximum observed concentration (Cmax) •PK parameter of BIIB076: Time to reach maximum observed concentration (Tmax) •PK parameter of BIIB076: Terminal elimination half-life (t1/2) •PK parameter of BIIB076: Clearance (CL) •PK parameter of BIIB076: Volume of distribution (Vd) •Number of participants with positive serum BIIB076 antibodies	Enrollment 56 Age 50 Years to 75 Years (Adult, Senior) Sex All	•Biogen	•Industry	Study Start February 17, 2017 Primary Completion March 8, 2018 Study Completion September 10, 2018 First Received February 15, 2017 Last Updated June 12, 2017 Last Verified June 2017 Results First Received No Study Results Posted

87	NCT02640092	Longitudinal Evaluation of [18F]MNI-798 as a PET Radioligand for Imaging Tau in the Brain of Patients With Alzheimer's Disease Compared to Healthy Volunteers	Title Acronym Other Ids: •GN30009 •g0097	Recruiting	•Alzheimer's Disease	•Drug: [18F]MNI-798	Study Types: Interventional Phase: Phase 1 Study Designs: •Intervention Model: Single Group Assignment •Masking: None (Open Label) •Primary Purpose: Diagnostic Outcome Measures: •Evaluate [18F]MNI-798 PET standard uptake value ratio (SUVr) as a marker for longitudinal change in tau burden by comparing 6-, 12- and 18- month SUVr to that at baseline\n •Correlate the change in [18F]MNI-798 PET SUVr to changes in cognition at 6-, 12- and 18- month. Cognition will be measured using multiple scales including the MMSE, CDR, ADAS-cog13, RBANS, and Stroop Color Word Scale\n •Correlate the change in [18F]MNI-798 PET SUVr to changes in CSF biomarker measures at 6-, 12- and 18- month. CSF biomarker measures will include tau, phosphor tau and amyloid-beta	Enrollment: 60 Age: 50 Years to 80 Years (Adult, Senior) Sex: All	•Genentech, Inc.	•Industry	Study Start: December 2015 Primary Completion: January 2018 Study Completion: January 2018 First Received: December 15, 2015 Last Updated: November 1, 2016 Last Verified: November 2016 Results First Received: No Study Results Posted

88	NCT02565511	A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease	Title Acronym: Generation S1 Other Ids: •CAPI015A2201J •2015-002715-15	Recruiting	•Alzheimer's Disease	•Biological: CAD106 Immunotherapy •Other: Placebo to CAD106 •Drug: CNP520 •Other: Placebo to CNP520	Study Types: Interventional Phase: •Phase 2 •Phase 3 Study Designs: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •Time to diagnosis of MCI due to Alzheimer's Disease (AD) or dementia due to Alzheimer's Disease •Change in the Alzheimer's Prevention Initiative Composite Cognitive (APCC) Test Score •Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) score •Number of participants with Adverse Events as a measure of Safety and Tolerability •Change on the Total Scale score and individual neurocognitive domain index scores of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) •Change in the Everyday Cognition scale (ECog) total scores •Change in Alzheimer's Disease related biomarkers •Change in APCC Test Score and CDR-SOB •A#-specific immune response	Enrollment: 1340 Age: 60 Years to 75 Years (Adult, Senior) Sex: All	•Novartis Pharmaceutica •Banner Alzheimer's Institute •National Institute on Aging (NIA) •Alzheimer's Association •Amgen •Novartis	•Industry •Other •NIH	Study Start: November 30, 2015 Primary Completion: May 6, 2024 Study Completion: May 6, 2024 First Received: September 28, 2015 Last Updated: September 6, 2017 Last Verified: September 2017 Results First Received: No Study Results Posted
89	NCT02564692	GeneMatch: A Program of the Alzheimer's Prevention Registry to Match Individuals to Studies Based on Apolipoprotein E (APOE) Genotype	Title Acronym Other Ids: APR-001	Recruiting	•Alzheimer Disease		Study Types: Observational Phase: Study Designs: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: •Number of individuals who enroll in GeneMatch •Number of individuals referred to research studies •Number of individuals who enroll in research studies	Enrollment: 500000 Age: 55 Years to 75 Years (Adult, Senior) Sex: All	•Banner Health	•Other	Study Start: November 2015 Primary Completion: December 2030 Study Completion: December 2030 First Received: September 29, 2015 Last Updated: November 18, 2016 Last Verified: November 2016 Results First Received: No Study Results Posted

90	NCT03131453	A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease	Title Acronym: Generation S2 Other Ids: •CCNP520A2202J •2016-002976-28	Recruiting	•Alzheimer's Disease	•Drug: CNP520 50mg •Drug: CNP520 15mg •Other: Placebo to CNP520	Study Types: Interventional Phase: •Phase 2 •Phase 3 Study Designs: •Allocation: Randomized •Intervention Model: Parallel Assignment •Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) •Primary Purpose: Treatment Outcome Measures: •Time to event •Change in the Alzheimer's Prevention Initiative Composite Cognitive (APCC) Test Score •Change in Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) score •Change on the Total Scale score and individual neurocognitive domain index scores of the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) •Change in the Everyday Cognition scale (ECog) total scores •Change in cerebral amyloid angiopathy (CAA) •Change on volume of brain regions •Change in amyloid deposition as measured by standardized uptake ratio (SUVR) of radiotracer positron emission tomography (PET) scan •Change in CSF levels of A#40, A#42 •Change in CSF levels of total tau and phosphorylated tau •Number of participants with adverse events as a measure of safety	Enrollment: 2000 Age: 60 Years to 75 Years (Adult, Senior) Sex: All	•Novartis Pharmaceutica •Amgen •Banner Alzheimer's Institute •Novartis	•Industry •Other	Study Start: August 3, 2017 Primary Completion: July 30, 2024 Study Completion: July 30, 2024 First Received: April 5, 2017 Last Updated: September 6, 2017 Last Verified: September 2017 Results First Received: No Study Results Posted
91	NCT00869817	Dominantly Inherited Alzheimer Network (DIAN)	Title Acronym: DIAN Other Ids: •IA0147 •U19AG032438	Recruiting	•Alzheimer's Disease		Study Types: Observational Phase: Study Designs: •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures: •Positive predictive power of a biomarker or group of biomarkers •Biomarkers obtained by blood draw, lumbar puncture, MRI, FDG PET, PET amyloid imaging •Clinical markers also examined from clinical interview and cognitive testing	Enrollment: 600 Age: 18 Years and older (Adult, Senior) Sex: All	•Washington University School of Medicine •National Institute on Aging (NIA)	•Other •NIH	Study Start: January 2009 Primary Completion: June 2019 Study Completion: June 2019 First Received: March 25, 2009 Last Updated: June 8, 2016 Last Verified: June 2016 Results First Received: No Study Results Posted

92	NCT00313495	Cooperative Huntington's Observational Research Trial	Title Acronym Other Ids COHORT	Recruiting	•Huntington Disease		Study Types Observational Phase Study Designs Time Perspective: Prospective Outcome Measures	Enrollment 5000 Age Child, Adult, Senior Sex All	•HP Therapeutics Foundation •Huntington Study Group	•Other	Study Start February 2006 Primary Completion December 2020 Study Completion December 2020 First Received April 10, 2006 Last Updated March 4, 2011 Last Verified March 2011 Results First Received No Study Results Posted
93	NCT02855476	HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease	Title Acronym HDClarity Other Ids 15/0519	Recruiting	•Huntington's Disease		Study Types Observational Phase Study Designs •Observational Model: Cohort •Time Perspective: Prospective Outcome Measures •Number of CSF samples banked •Huntingtin protein level in cerebrospinal fluid •Kynurenine metabolites in cerebrospinal fluid	Enrollment 600 Age 21 Years to 75 Years (Adult, Senior) Sex All	•University College, London	•Other	Study Start January 2017 Primary Completion July 2019 Study Completion July 2020 First Received July 26, 2016 Last Updated August 21, 2017 Last Verified August 2017 Results First Received No Study Results Posted